Literature DB >> 26250586

miR-34c-3p functions as a tumour suppressor by inhibiting eIF4E expression in non-small cell lung cancer.

Fang Liu1, Xuefeng Wang2, Jiebing Li3, Kuo Gu4, Liyan Lv5, Shuai Zhang1, Dehai Che1, Jingyan Cao1, Shi Jin1, Yan Yu1.   

Abstract

OBJECTIVES: MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression and mediate diverse physiological processes. In this study, we investigated functions of miRNA miR-34c-3p in non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: miR-34c-3p expression was evaluated by qPCR. Cell viability was examined by MTT and proliferation by cell cycle analysis. Cell migration and invasion were tested using Transwells with/without Matrigel coating. Western blot analysis was performed for eIF4E, c-Myc, Cyclin D1, survivin and Mcl-1 protein expression.
RESULTS: miR-34c-3p expression was significantly reduced in tissues and serum samples from NSCLC patients and in NSCLC cell lines A549, H460, H23, H157 and H1299. Overexpression of miR-34c-3p in A549 and H157 cells reduced cell proliferation, migration and invasion, whereas transfection with miR-34c-3p inhibitor (miR-34c-3p-in) produced opposite effects. Target analysis using algorithms miRanda, TargetScan and DIANA identified eIF4E as a potential target of miR-34c-3p. Luciferase assay using the eIF4E 3'-UTR reporter carrying a putative miR-34c-3p target sequence revealed eIF4E to be a specific target of miR-34c-3p. Overexpression of miR-34c-3p in NSCLS cell lines led to significant reduction in mRNA and protein levels of eIF4E, whereas inhibition of miR-34c-3p resulted in significant increase in eIf4e protein levels, confirming eIF4E to be a direct target of miR-34c-3p in NSCLS. Overexpression of eIF4E in A549 cells promoted cell proliferation, migration and invasion, which were partially reversed by miR-34c-3p.
CONCLUSION: miR-34c-3p directly targeted eIF4E and reduced miR-34c-3p expression in NSCLC, promoting cell cycle progression, proliferation, migration and invasion.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26250586      PMCID: PMC6496344          DOI: 10.1111/cpr.12201

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  49 in total

1.  Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.

Authors:  Nizar J Bahlis; Jennifer McCafferty-Grad; Ileana Jordan-McMurry; Jim Neil; Isildinha Reis; Mohamed Kharfan-Dabaja; James Eckman; Mark Goodman; Hugo F Fernandez; Lawrence H Boise; Kelvin P Lee
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

2.  Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung.

Authors:  I B Rosenwald; M J Hutzler; S Wang; L Savas; A E Fraire
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

3.  Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.

Authors:  A J Waskiewicz; J C Johnson; B Penn; M Mahalingam; S R Kimball; J A Cooper
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

4.  Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.

Authors:  C C Jiang; A Croft; H-Y Tseng; S T Guo; L Jin; P Hersey; X D Zhang
Journal:  Oncogene       Date:  2013-06-17       Impact factor: 9.867

5.  MicroRNAs block assembly of eIF4F translation initiation complex in Drosophila.

Authors:  Takashi Fukaya; Hiro-Oki Iwakawa; Yukihide Tomari
Journal:  Mol Cell       Date:  2014-10-02       Impact factor: 17.970

6.  MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.

Authors:  Michela Garofalo; Young-Jun Jeon; Gerard J Nuovo; Justin Middleton; Paola Secchiero; Pooja Joshi; Hansjuerg Alder; Natalya Nazaryan; Gianpiero Di Leva; Giulia Romano; Melissa Crawford; Patrick Nana-Sinkam; Carlo M Croce
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

Review 7.  Oncogenic micro-RNAs and Renal Cell Carcinoma.

Authors:  Cristina Grange; Federica Collino; Marta Tapparo; Giovanni Camussi
Journal:  Front Oncol       Date:  2014-03-17       Impact factor: 6.244

8.  Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells.

Authors:  Zhendong Wu; Yupeng Wu; Ye Tian; Xiaofeng Sun; Jixiang Liu; Hongbo Ren; Chaohui Liang; Ligang Song; Hongchao Hu; Liqun Wang; Baohua Jiao
Journal:  Oncol Lett       Date:  2013-09-12       Impact factor: 2.967

9.  A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

Authors:  A L Kasinski; K Kelnar; C Stahlhut; E Orellana; J Zhao; E Shimer; S Dysart; X Chen; A G Bader; F J Slack
Journal:  Oncogene       Date:  2014-09-01       Impact factor: 9.867

Review 10.  Mir-34: a new weapon against cancer?

Authors:  Gabriella Misso; Maria Teresa Di Martino; Giuseppe De Rosa; Ammad Ahmad Farooqi; Angela Lombardi; Virginia Campani; Mayra Rachele Zarone; Annamaria Gullà; Pierosandro Tagliaferri; Pierfrancesco Tassone; Michele Caraglia
Journal:  Mol Ther Nucleic Acids       Date:  2014-09-23       Impact factor: 10.183

View more
  16 in total

1.  Circulating microRNA signature of steroid-induced osteonecrosis of the femoral head.

Authors:  Zheng Li; Chao Jiang; Xingye Li; William K K Wu; Xi Chen; Shibai Zhu; Chanhua Ye; Matthew T V Chan; Wenwei Qian
Journal:  Cell Prolif       Date:  2017-12-04       Impact factor: 6.831

2.  miR-34c-3p inhibits cell proliferation, migration and invasion of hepatocellular carcinoma by targeting MARCKS.

Authors:  Jianjun Song; Qi Wang; Yongyun Luo; Peng Yuan; Chaofeng Tang; Yongfeng Hui; Zuozheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 3.  Emerging roles of MicroRNAs in osteonecrosis of the femoral head.

Authors:  Zheng Li; Bo Yang; Xisheng Weng; Gary Tse; Matthew T V Chan; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2017-11-12       Impact factor: 6.831

4.  MicroRNA-665 suppressed the invasion and metastasis of osteosarcoma by directly inhibiting RAB23.

Authors:  Chenhui Dong; Quanyin Du; Zimin Wang; Yu Wang; Siyu Wu; Aimin Wang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

5.  Inhibitory Effect of MiR-449b on Cancer Cell Growth and Invasion through LGR4 in Non-Small-Cell Lung Carcinoma.

Authors:  Dong Yang; Jin-Song Li; Qian-Yu Xu; Tian Xia; Jia-Hong Xia
Journal:  Curr Med Sci       Date:  2018-08-20

6.  miRNA-34c inhibits myoblasts proliferation by targeting YY1.

Authors:  Meng Wang; Chuncheng Liu; Yang Su; Kuo Zhang; Yuying Zhang; Min Chen; Mengxu Ge; Lijie Gu; Tianyu Lu; Ning Li; Zhengquan Yu; Qingyong Meng
Journal:  Cell Cycle       Date:  2017-01-26       Impact factor: 4.534

7.  Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Ke Zhao; Jing Cheng; Baojun Chen; Qi Liu; Di Xu; Yongjian Zhang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

8.  4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.

Authors:  Blake A Jacobson; Zeeshan Ahmad; Sierra Chen; Gabriella Waldusky; Maxwell Dillenburg; Emilia Stoian; Daniel A Cambron; Anil J Patel; Manish R Patel; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2020-11-23       Impact factor: 3.850

Review 9.  New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.

Authors:  Erika Larrea; Carla Sole; Lorea Manterola; Ibai Goicoechea; María Armesto; María Arestin; María M Caffarel; Angela M Araujo; María Araiz; Marta Fernandez-Mercado; Charles H Lawrie
Journal:  Int J Mol Sci       Date:  2016-04-27       Impact factor: 5.923

10.  MicroRNA-34c Suppresses Breast Cancer Migration and Invasion by Targeting GIT1.

Authors:  Wei-Yang Tao; Chun-Yang Wang; Yong-Hui Sun; Yong-Hui Su; Da Pang; Guo-Qiang Zhang
Journal:  J Cancer       Date:  2016-07-25       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.